Neurocrine Biosciences Officer Files Form 144 for $361K Share Sale
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Neurocrine Biosciences Inc ($NBIX) Form 144 Notice Insider: Matthew C. Abernethy (Officer) Proposed Sale: 2,311 shares of Common Stock (~$361,024) Broker: Morgan Stanley Smith Barney LLC Plan Date: Adopted May 22, 2026 (Rule 10b5-1) Significance: Low
Comprehensive Analysis
Form 144 Filing Overview
- Issuer: Neurocrine Biosciences Inc ($NBIX)
- Insider: Matthew C. Abernethy, Officer
- Filing Date: September 14, 2026
- Approximate Sale Date: September 14, 2026
Transaction Details
- Securities Offered: 2,311 shares of Common Stock
- Estimated Aggregate Market Value: $361,024.42 (~$156.22 per share)
- Acquisition Origin: Performance Stock Units vesting on September 14, 2026
- Trading Plan: Executed under a pre-established Rule 10b5-1 trading plan adopted on May 22, 2026
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
Analysis & Significance
This planned transaction is of Low trading significance. The sale represents a tiny fraction of the company's 101,649,181 shares outstanding and is executed pursuant to a pre-scheduled Rule 10b5-1 trading plan tied to vesting performance equity.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.